We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 16

Natural health products and adverse reactions: remembering to report
  • Gowling WLG
  • Canada
  • October 31 2011

As Health Canada shifts to a proactive phase of enforcement of the Natural Health Products Regulations, it is important for natural health product (NHP) licence holders to ensure they have policies in place to monitor, assess and report adverse reactions to their products.


A licensing regime for food importers?
  • Gowling WLG
  • Canada
  • January 14 2011

The Canadian Food Inspection Agency (CFIA) is considering adopting a licensing regime that would apply to all importers of food products or food ingredients in the non-federally registered sector (NFRS).


Assessment of Batch 9 substances completed
  • Gowling WLG
  • Canada
  • October 20 2010

Final assessments of the substances in Batch 9 of the "Challenge" program under the Chemicals Management Plan have been completed.


Health Canada considers changes to precautionary labelling of priority allergens
  • Gowling WLG
  • Canada
  • June 9 2010

Health Canada and the Canadian Food Inspection Agency are considering four potential policy options to update their position on precautionary labelling of priority allergens.


Health Products & Food Branch policy on counterfeit health products
  • Gowling WLG
  • Canada
  • May 21 2010

By a document posted May 14, 2010, the Health Products & Food Branch Inspectorate have set out guiding principles of Health Canada's decision making framework for identifying, assessing and managing health risks to identify the issues of counterfeit health products.


Health Canada releases final guidance on biosimilars
  • Gowling WLG
  • Canada
  • March 25 2010

On March 8, 2010, Health Canada released its final guidance documents relating to the approval pathway for subsequent entry biologics (SEBs) in Canada.


Harry Dahme
  • Gowling WLG

Isabel Raasch
  • Gowling WLG

Scott A. Smith
  • Gowling WLG

Scott E. Foster
  • Gowling WLG